Key statistics
On Thursday, Summit Therapeutics Inc (SMMT*:MEX) closed at 378.00, -12.09% below its 52-week high of 430.00, set on Oct 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 378.00 |
---|---|
High | 378.00 |
Low | 378.00 |
Bid | -- |
Offer | -- |
Previous close | 378.00 |
Average volume | 124.00 |
---|---|
Shares outstanding | 735.16m |
Free float | 113.02m |
P/E (TTM) | -- |
Market cap | 14.03bn USD |
EPS (TTM) | -0.2299 USD |
Data delayed at least 20 minutes, as of Oct 03 2024 17:29 BST.
More ▼
Press releases
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC
- PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
- Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
- Summit Therapeutics Raises $235 Million
- Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
- HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024
- Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024
- Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024
- Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab
More ▼